Virax Biolabs (VRAX) Accounts Payables (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Accounts Payables of $309463.0 for Q1 2026, up 23.7% year-over-year from $250170.0 in Q1 2025, and up 23.7% quarter-over-quarter from $250170.0 in Q1 2025.
Virax Biolabs (VRAX) Accounts Payables (2021 - 2026) Analysis & Trends
Virax Biolabs' Accounts Payables history runs 6 years deep, the most recent figure standing at $309463.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 23.7% year-over-year to $309463.0; the TTM figure through Mar 2026 stood at $309463.0 (up 23.7% YoY), while the FY2026 annual figure was $309463.0, up 23.7% from the prior year.
- Accounts Payables for Q1 2026 stood at $309463.0, up from $250170.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.1 million in Q1 2022, with the low at $120894.0 in Q1 2024.
- The 5-year median for Accounts Payables is $279816.5 (2025), against an average of $396462.2.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 413.7% in 2022, then tumbled 85.66% in 2023.
- Virax Biolabs' Accounts Payables stood at $1.1 million in 2022, then sank by 85.66% to $159908.0 in 2023, then soared by 164.44% to $422865.0 in 2024, then tumbled by 40.84% to $250170.0 in 2025, then gained by 23.7% to $309463.0 in 2026.
- Business Quant data shows VRAX's Accounts Payables at $309463.0 in Q1 2026, $250170.0 in Q1 2025, and $422865.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 309,463.00 |
| Mar 31, 2025 | 250,170.00 |
| Sep 30, 2024 | 422,865.00 |
| Mar 31, 2024 | 120,894.00 |
| Mar 31, 2023 | 159,908.00 |
| Mar 31, 2022 | 1.12 Mn |
| Mar 31, 2021 | 217,145.00 |